The real drug development delay? Bad communication.

Swiss pharmaceutical giant Novartis has agreed to buy London-based biotech Myricx Bio for up to $1.5bn (£1.1bn) as global ...

VERAXA Biotech (NASDAQ: VRXA) provided a corporate and pipeline update highlighting progress during the first half of 2026, ...

They have at least one thing in common: An exciting pipeline.

Candel Therapeutics (CADL) shifts to late-stage oncology with CAN-2409 Phase III wins and BLA catalyst. Read here for a ...

Parabilis Medicines, NewLimit, Enliven Therapeutics, and Kardigan bagged the biggest biotech funding rounds overall in June 2026.

Novartis will pay $1.1bn upfront and up to $400m in milestones for Myricx Bio, a UK firm developing a novel payload for antibody-drug conjugates.

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

Biotech companies are spending billions to perfect chemical formulas, only to be tripped up by the one variable they forgot ...

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.

David Craig’s operating manual for building biotech companies in today’s market is now available in hardcover and as an ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...